Quantcast
Last updated on April 23, 2014 at 11:31 EDT

Latest Anticoagulants Stories

2012-05-09 02:27:35

RARITAN, N.J., May 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome (ACS). XARELTO(® )currently is under review with the U.S. FDA to reduce the risk of secondary...

2012-05-04 10:25:52

CHICAGO, May 4, 2012 /PRNewswire/ -- Data presented by CSL Behring today at the 2012 Thrombosis and Hemostasis Summit of North America (THSNA) showed that the safety profile of human 4-factor prothrombin complex concentrate (PCC) is consistent with the current standard of treatment in patients receiving vitamin K antagonist therapy (i.e., warfarin) for acute bleeding or prior to emergency surgery. The results are from the first large-scale controlled clinical trials comparing a 4-factor PCC...

2012-05-04 06:22:50

CHICAGO, May 4, 2012 /PRNewswire/ -- Data presented today by CSL Behring at the 2012 Thrombosis and Hemostasis Summit of North America (THSNA) showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping bleeding in patients receiving vitamin K antagonist therapy (i.e., warfarin). Currently in the United States, fresh frozen plasma is the standard treatment for warfarin reversal. The data are from the first and...

Aspirin Vs. Warfarin: Both Effective For Heart Failure Treatment
2012-05-03 08:22:43

Less costly aspirin is as effective for heart failure patients with normal heart rhythm as other more expensive drugs, such as warfarin, according to breakthrough research published in today´s New England Journal of Medicine. Researchers, led by clinical principal investigator Shunichi Homma, MD, of Columbia University Medical Center in New York and statistical principal investigator John L.P. (Seamus) Thompson, PhD, of Columbia University´s Mailman School of Public Health, found...

2012-05-03 02:32:08

RIDGEFIELD, Conn., May 3, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the launch of the GLORIA(TM)-AF Registry Program, the largest prospective observational study in non-valvular atrial fibrillation (NVAF) planned at this time. With a goal of enrolling 56,000 patients, the registry aims to understand the long-term use of antithrombotic treatments to reduce the risk of stroke in patients with NVAF. GLORIA-AF will follow newly-diagnosed...

2012-05-02 02:28:13

RARITAN, N.J., May 2, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen), announced today that it has submitted supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent venous thromboembolism (VTE). These submissions are supported by data from the...

2012-04-25 20:20:59

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging Science Series webinar. Patients with certain types of atrial fibrillation, or irregular heartbeat, take these drugs to reduce the risks of clots that could lead to a stroke. Sometimes they are instructed to stop taking the medication temporarily before surgery or...

2012-04-23 02:21:41

Bayer Inc. welcomes support for public reimbursement of new treatment TORONTO, April 23, 2012 /PRNewswire/ - Hundreds of thousands of Canadians living with atrial fibrillation (AF) are now one step closer to getting public reimbursement for a new stroke prevention therapy - news that was welcomed today by Bayer Inc. The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR), has positively recommended to Canada's provincial and...

2012-04-18 02:28:32

RIDGEFIELD, Conn., April 18, 2012 /PRNewswire/ -- A new retrospective sub-analysis of the 18,113 patient RE-LY® trial showed lower rates of intracranial hemorrhage (ICH), including both fatal and traumatic ICH, for Pradaxa® (dabigatran etexilate mesylate) capsules 150mg taken twice daily compared with warfarin. Results of the sub-analysis recently were published online in Stroke: The Journal of the American Heart Association. Intracranial hemorrhage can be a devastating complication...

2012-04-03 02:24:48

MOUNTAIN VIEW, Calif., April 3, 2012 /PRNewswire/ -- The U.S. anticoagulant market is on the verge of a major shift in clinical practice. It is transitioning from a market dominated by a single injectable anticoagulant to a highly competitive one dominated by first-in-class novel oral anticoagulants. Companies are vying with each other to introduce novel therapies that offer superior safety, efficacy and convenience to patients and physicians. This is a medical need that has been unmet for...